1-cyclohexyl-3-[(3S,3aR,6S,6aS)-6-(pyridin-2-yloxy)-hexahydro-furo[3,2-b]furan-3-yl]-urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: 1-cyclohexyl-3-[(3S,3aR,6S,6aS)-6-(pyridin-2-yloxy)-hexahydro-furo[3,2-b]furan-3-yl]-urea
• 英文别名: 1-[(3S,3aR,6S,6aS)-6-pyridin-2-yloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]-3-cyclohexylurea
• 化学式: C₁₈H₂₅N₃O₄
• 分子量: 347.4
• InChiKey: KNKWXHBBVFQUNW-XJNFMUPTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  81.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-羟基吡啶 、 potassium tert-butylate 、 toluene-4-sulfonic acid (3R,3aS,6S,6aR)-6-(3-cyclohexyl-ureido)-hexahydro-furo[3,2-b]furan-3-yl ester 在 acetonitrile-water 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.25h， 以to give 41 mg (33%) of 1-cyclohexyl-3-[(3S,3aR,6S,6aS)-6-(pyridin-2-yloxy)-hexahydro-furo[3,2-b]furan-3-yl]-urea along with 19 mg (15%) of the regioisomeric 1-cyclohexyl-3-[(3S,3aR,6S,6aR)-6-(2-oxo-2H-pyridin-1-yl)-hexahydro-furo[3,2-b]furan-3-yl]-urea的产率得到1-cyclohexyl-3-[(3S,3aR,6S,6aS)-6-(pyridin-2-yloxy)-hexahydro-furo[3,2-b]furan-3-yl]-urea
  参考文献：
  名称：

  ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

  摘要：

  本发明涉及式(I)的化合物，其中R1，R11，R12和X具有声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们是高效、选择性可溶性环氧酶抑制剂，适用于肾衰竭、糖尿病性肾病、2型糖尿病、炎症的治疗和预防，或者在疼痛、血脂异常和动脉粥样硬化方面可能显示出有益的效果。本发明还涉及制备式(I)化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。

  公开号：

  US20150336979A1

文献信息

• US9540391B2
  申请人：——

  公开号：US9540391B2

  公开（公告）日：2017-01-10
• [EN] ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE<br/>[FR] DÉRIVÉS D'ISOMANNIDE UTILISÉS COMME INHIBITEURS D'ÉPOXYDE HYDROLASE SOLUBLE
  申请人：SANOFI SA

  公开号：WO2014111465A1

  公开（公告）日：2014-07-24

  The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
• ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：SANOFI

  公开号：US20150336979A1

  公开（公告）日：2015-11-26

  The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式(I)的化合物，其中R1，R11，R12和X具有声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们是高效、选择性可溶性环氧酶抑制剂，适用于肾衰竭、糖尿病性肾病、2型糖尿病、炎症的治疗和预防，或者在疼痛、血脂异常和动脉粥样硬化方面可能显示出有益的效果。本发明还涉及制备式(I)化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。